Sign in
SGMT Stock Price, Chart, Stats & News
Sagimet Biosciences Inc. Series A Common Stock
Save
Sagimet Biosciences Inc. Series A Common Stock (SGMT) does not currently pay a dividend.
232.96M
Market cap
–
Current P/E
–
Forward P/E
SGMT chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -43.82% |
ROE | -40.85% |
D/E | 0.00x |
Interest coverage ratio | – |
SGMT valuation
P/E | – |
P/S | – |
P/B | 1.42x |
P/CF | -3.46x |
P/FCF | -3.43x |
P/OCF | -3.46x |
PEG | -0.28x |
EV multiple | -3.37x |
About
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma.
Similar securities
Based on sector and market capitalization
Report issue